Novartis: Synnovation Deal And 8% Full-Year 2025 Sales Growth (NYSE:NVS)

Group 1 - The article discusses Novartis (NVS) and highlights its continued value growth driven by products with double-digit percentage growth [2] - The author, Terry Chrisomalis, has extensive experience in the biotech sector and provides in-depth analysis through the Biotech Analysis Central service [2] - The Biotech Analysis Central service includes a library of over 600 biotech investing articles and a model portfolio of small and mid-cap stocks [2] Group 2 - The article does not contain any stock positions or plans to initiate positions in the companies mentioned [3] - There is no compensation received for the article other than from Seeking Alpha, indicating an independent analysis [3] - Seeking Alpha clarifies that past performance does not guarantee future results and that the views expressed may not reflect the platform's overall stance [4]